Bausch Health
BHC
6.15
+0.13
+2.16%
Bausch Health
US · BHC
#2722 by market cap
Listed 1970
6.15
+0.13
+2.16%
Live - 5344 symbols - heartbeat 43s ago
· 2026-10-08 06:55
Pre-market
5.60
-8.92%
After-hours
6.15
0.00%
- Market cap
- 2.30B
- P/E (TTM)i
- -2.09
- P/Bi
- -1.30
- EPSi
- 0.42
- Div yieldi
- 0.00%
- 52W posi
- 50%
Reader sentiment
Are you bullish or bearish on BHC?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 0.29, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +6.66% YoY
Margins
- Gross margin
- 70.65%
- Operating margin
- 21.28%
- Net margin
- 1.53%
Key ratios & quality
- Enterprise valuei
- 21.82B
- Altman Z-Scorei
- 0.29
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.38B | 8.60B | 8.03B | 8.43B | 8.12B | 8.76B | 9.63B | 10.27B |
| Gross profit | 6.03B | 6.25B | 5.78B | 6.04B | 5.76B | 6.20B | 6.84B | 7.25B |
| Selling & admin expenses | 2.47B | 2.55B | 2.37B | 2.62B | 2.63B | 2.92B | 3.30B | 3.44B |
| Research & development | 413.00M | 512.00M | 484.00M | 473.00M | 529.00M | 604.00M | 616.00M | 629.00M |
| Operating profit | 499.00M | 1.29B | 1.28B | 1.57B | 1.39B | 1.60B | 1.85B | 2.19B |
| Pretax profit | -4.15B | -1.84B | -934.00M | -1.02B | -129.00M | -390.00M | 167.00M | 367.00M |
| Tax | -10.00M | -54.00M | -375.00M | -87.00M | 83.00M | 221.00M | 239.00M | 247.00M |
| Net profit | -4.14B | -1.78B | -559.00M | -937.00M | -212.00M | -611.00M | -72.00M | 120.00M |
| Basic EPS | -12 | -5 | -2 | -3 | -1 | -2 | 0 | 0 |
| Diluted EPS | -11.81 | -5.08 | -1.58 | -2.64 | -0.62 | -1.62 | -0.13 | 0.42 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 2.26B | 2.53B | 2.68B | 2.80B | 2.52B | 2.85B |
| Gross profit | 1.56B | 1.77B | 1.93B | 2.00B | 1.79B | 2.08B |
| Selling & admin expenses | 867.00M | 894.00M | 795.00M | 882.00M | 861.00M | 907.00M |
| Research & development | 143.00M | 159.00M | 247.00M | 51.00M | 163.00M | 173.00M |
| Operating profit | 292.00M | 457.00M | 636.00M | 829.00M | 521.00M | 775.00M |
| Pretax profit | -47.00M | 140.00M | 218.00M | 56.00M | -1.35B | 348.00M |
| Tax | 39.00M | 12.00M | 37.00M | 159.00M | 77.00M | 88.00M |
| Net profit | -86.00M | 128.00M | 181.00M | -103.00M | -1.43B | 260.00M |
| Basic EPS | 0 | 0 | 0 | 0 | -4 | 1 |
| Diluted EPS | -0.16 | 0.40 | 0.48 | -0.30 | -3.82 | 0.68 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 4.21B | 6.97B | 5.34B | 5.61B | 4.25B | 5.60B | 5.77B | 6.16B |
| Cash & ST investments | 721.00M | 3.24B | 605.00M | 582.00M | 564.00M | 947.00M | 1.18B | 1.31B |
| Inventory | 934.00M | 1.11B | 1.09B | 993.00M | 1.09B | 1.54B | 1.60B | 1.63B |
| Total assets | 32.49B | 33.86B | 31.20B | 29.20B | 25.69B | 27.35B | 26.52B | 26.37B |
| Total current liabilities | 3.84B | 6.25B | 4.91B | 5.20B | 3.94B | 4.30B | 6.75B | 4.18B |
| Short-term debt | 228.00M | 1.23B | -- | -- | 432.00M | 450.00M | 2.67B | 236.00M |
| Long-term debt | 24.08B | 24.66B | 23.93B | 22.65B | 20.33B | 21.94B | 18.94B | 20.59B |
| Total liabilities | 29,677,000,000.00 | 32,727,000,000.00 | 30,594,000,000.00 | 29,236,000,000.00 | 25,426,000,000.00 | 27,432,000,000.00 | 26,845,000,000.00 | 25,989,000,000.00 |
| Total equity | 2.82B | 1.14B | 605.00M | -34.00M | 260.00M | -82.00M | -322.00M | 377.00M |
| Retained earnings | -5.66B | -7.45B | -8.01B | -8.96B | -9.19B | -9.78B | -9.82B | -9.67B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 5.73B | 6.51B | 6.25B | 6.16B | 5.98B | 6.52B |
| Cash & ST investments | 1.13B | 1.73B | 1.31B | 1.31B | 1.30B | 1.83B |
| Inventory | 1.61B | 1.66B | 1.60B | 1.63B | 1.60B | 1.60B |
| Total assets | 26.42B | 27.27B | 26.82B | 26.37B | 24.50B | 24.79B |
| Total current liabilities | 4.26B | 4.98B | 4.79B | 4.18B | 4.53B | 4.54B |
| Short-term debt | 282.00M | 879.00M | 579.00M | 236.00M | 900.00M | 881.00M |
| Long-term debt | 21.23B | 20.86B | 20.46B | 20.59B | 19.88B | 19.88B |
| Total liabilities | 26,661,000,000.00 | 27,119,000,000.00 | 26,468,000,000.00 | 25,989,000,000.00 | 25,580,000,000.00 | 25,596,000,000.00 |
| Total equity | -240.00M | 147.00M | 356.00M | 377.00M | -1.08B | -802.00M |
| Retained earnings | -9.88B | -9.73B | -9.56B | -9.67B | -11.09B | -10.83B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1.50B | 1.50B | 1.11B | 1.43B | -728.00M | 1.03B | 1.60B | 1.40B |
| Depreciation & amortization | 2.82B | 2.08B | 1.83B | 1.55B | 1.39B | 1.26B | 1.27B | 1.21B |
| Free cash flow | 1.27B | 1.22B | 802.00M | 1.14B | -996.00M | 760.00M | 1.26B | 993.00M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 0 | 0 | 675.00M | -- | -- | -- |
| Ending cash balance | 723.00M | 3.24B | 1.82B | 2.12B | 591.00M | 962.00M | 1.20B | 1.33B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 211.00M | 289.00M | 405.00M | 495.00M | 230.00M | 670.00M |
| Depreciation & amortization | 305.00M | 307.00M | 306.00M | 290.00M | 295.00M | 281.00M |
| Free cash flow | 87.00M | 189.00M | 314.00M | 403.00M | 83.00M | 593.00M |
| Dividends paid | 0 | 0 | 0 | -- | 0 | 0 |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 1.16B | 1.74B | 1.34B | 1.33B | 1.31B | 1.84B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -96.67 | -94.20 | -70.09 | -441.96 | -- | -- | -- | -- |
| ROA %i | -11.85 | -5.39 | -1.72 | -3.14 | -0.82 | -2.23 | -0.17 | 0.59 |
| ROIC %i | -8.50 | -0.87 | 2.22 | 1.49 | -- | -- | -- | -- |
| 5-year avg ROE %i | -16.94 | -39.17 | -52.14 | -129.90 | -- | -- | -- | -- |
| EBIT margin %i | -29.46 | -2.62 | 7.47 | 4.77 | 16.43 | 10.71 | 16.16 | 19.20 |
| FCF / sales %i | 15.11 | 14.22 | 9.99 | 13.55 | -- | 8.68 | 13.06 | 9.67 |
| Current ratioi | 1.10 | 1.12 | 1.09 | 1.08 | 1.08 | 1.30 | 0.86 | 1.47 |
| Quick ratioi | 0.67 | 0.81 | 0.44 | 0.45 | 0.60 | 0.68 | 0.49 | 0.88 |
| Debt / assetsi | 74.80 | 76.47 | 76.69 | 77.58 | 80.85 | 81.86 | 81.50 | 79.08 |
| LT debt / equityi | 880.97 | 2,319.94 | 4,471.96 | -- | -- | -- | -- | -- |
| Interest coveragei | -1.47 | -0.14 | 0.39 | 0.28 | 0.91 | 0.71 | 1.12 | 1.23 |
| Revenue CAGR (3Y) %i | -7.09 | -3.84 | -2.74 | 0.21 | -1.88 | 2.94 | 4.50 | 8.11 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -13.47 | -12.02 | -25.68 | -3.35 | -- | -1.78 | 3.22 | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -- | -- |
| ROA %i | -0.15 | 0.36 | 1.36 | 0.59 | -4.74 | -4.22 |
| ROIC %i | -- | -- | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 15.95 | 17.84 | 20.58 | 19.20 | 6.99 | 8.06 |
| FCF / sales %i | 12.50 | 11.20 | 10.81 | 9.67 | 9.39 | 12.84 |
| Current ratioi | 1.35 | 1.31 | 1.30 | 1.47 | 1.32 | 1.44 |
| Quick ratioi | 0.75 | 0.79 | 0.78 | 0.88 | 0.77 | 0.90 |
| Debt / assetsi | 81.41 | 79.73 | 78.44 | 79.08 | 84.88 | 83.81 |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | 1.14 | 1.19 | 1.34 | 1.23 | 0.44 | 0.54 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Product sales is the largest reported line at 99.05% of revenue, across 2 reported segments.
- The next-largest line, Other revenues, is a distant second at 0.95% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Product sales99.05%
Other revenues0.95%
Quote time 2026-10-08 06:55:45 · For reference only, not investment advice and not tailored to your situation.